. Author manuscript; available in PMC: 2015 Jan 1.

Published in final edited form as: J Clin Virol. 2013 Nov 1;59(1):30–37. doi: 10.1016/j.jcv.2013.10.028

Table 2. Multiply primed RCA preferentially amplifies HPV DNA from a variety of clinical samples.

Eleven samples went through MP-RCA. Both HPV and β-actin were quantified before and after RCA reaction, relative enrichment for HPV is calculated.

Sample		Diagnosis	Virus present	HPV		ACTB		Enrichment^*
ID	Type	Diagnosis	Virus present	Before RCA (Ct)	After RCA (Ct)	Original (Ct)	After RCA (Ct)	Enrichment^*
C1	Siha		HPV 16	25.81	23.22	25.90	25.34	4.1
C2	Siha+HPV16p		HPV 16	26.20	19.37	26.98	25.48	40.2
CS1	Anal swab	Neg	HPV 16	22.50	15.34	31.19	35.66	3184.0
CS2	Anal swab	Neg	HPV 16	31.29	27.95	30.35	34.20	146.3
CS3	Anal swab	Neg	HPV 16	21.02	12.44	29.89	33.30	4093.9
CS4	Cervical swab	Neg	HPV 16	29.99	27.52	25.62	33.93	1756.4
CS5	Cervical swab	Neg	HPV 16	37.18	24.88	26.19	30.54	103418.3
CS6	Cervical swab	Neg	HPV 16	32.71	14.20	25.82	30.79	11725814.7
CS7	Oral lavage	Neg	HPV16	33.48	14.07	25.71	25.39	558036.5
CS8	Oral lavage	Neg	HPV16	36.70	18.34	25.30	26.59	822696.1
CS9	Oral lavage	Neg	HPV 59	29.71	21.64	28.57	33.28	7033.4

Enrichment was calculated using the 2^−ΔΔCt method, where ΔΔCt= [Ct_HPV(after RCA)- Ct_HPV(before RCA)]- [Ct_ACTB(after RCA)-Ct_ACTB(before RCA)]